Screener / SEC EDGAR /CIK 0001674416 /10-K filed Feb 12, 2026, compared with Feb 11, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CRISPR Therapeutics AG CRSP

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of CRSP's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Jun 13, 2022
Questions asked 40 each answered in the company's own letter
No closing letter 2 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 9 UPLOAD
  2. 2. Questions in them 40 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 2 of 4 closing letter

Half the closed reviews took 30 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2021

2022-06-13 to 2022-07-13 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2022-07-13
Results discussion (MD&A)
Results of Operations · Research and Development Expenses, page 130
SEC asked
We note your disclosure that except for activities you perform in connection with your collaborations with Vertex and ViaCyte, as well as in connection with the Bayer Transaction, you do not track research and development costs on a program-by-program basis.
Rest of the question

Please provide us with proposed disclosure to be included in future periodic reports which separately quantifies your research and development expense related to ViaCyte and in connection with the Bayer Transaction. For the remaining expenses, please disclose by disease area or stage of development (i.e. pre-clinical and clinical). If this break out is not possible, provide disclosure of total research and development expenses incurred during each period presented by nature which should reconcile to total research and development expense on the Statements of Operations.

CRSP answered
No. 1. The Company respectfully acknowledges the Staff’s comment and advises the Staff that with respect to research and development expenses attributable to its collaborations with Vertex, ViaCyte and the Bayer

Transaction (as such terms are defined in the Company’s filings with the Commission), the Company has disclosed such expenses that in its judgement are material to the understanding of its results of operations.
Rest of the answer

Specifically, with respect to

Vertex, beginning with the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2022 that was filed with the Commission on May 9, 2022, the Company has separately disclosed collaboration costs under its collaboration with Vertex as, “Collaboration Expense, Net”, on its own line under “Operating Expenses” on pages 21-22 and described in more detail on page 20.

Management has determined that expenses attributable to the Company’s other collaborations and partnerships, including with ViaCyte and in connection with the Bayer Transaction, are not material to an understanding of its results of operations at this time and therefore do not warrant separate disclosure. If, and to the extent, management determines research and development expenses in connection with any of its collaborations or partnerships are material to the understanding of the

Company’s results of operations, such expenses will be separately disclosed in future periodic reports.

In addition, the Company respectfully advises the Staff that it classifies its research and development expenses as either external or internal. The Company’s external research and development expenses support its various preclinical and clinical programs, and as such the Company does not break down external research and development expenses further. The Company’s internal research and development expenses consist of payroll and benefits expenses, facilities expense, and other indirect research and development expenses incurred in support of overall research and development activities and as such are not allocated to a specific development stage or therapeutic area.

Page

Further, the Company respectfully advises the Staff that, in addition to its existing tabular disclosure regarding the Company’s results of operations (which is inclusive of research and development expenses) and discussion of research and development expenses across periods, the Company intends to include the following disclosure in its future periodic reports to provide additional detail about its’ external and internal research and development expenses:

Expenses

Research and development expenses were $[ ] for the [period] ended [date], compared to $[ ] for the [period] ended [date]. The following table summarizes our research and development expenses for the [period] ended [date] and [date], together with the changes in those items in dollars (in thousands):

[Year][X-months] ended [DATE]

[Year]

Change

External research and development expenses

$

[

]

Employee related expenses

Facility expenses

Stock-based compensation expenses

Other expenses

Sublicense and license fees

Total

The [increase][decrease] of approximately $[ ] was primarily attributable to the following:

•

$[ ] of [increased][decreased] external research and development costs, primarily related to [ ];

$[ ] of [increased][decreased] employee related expenses, primarily related to

[ ];

$[ ] of [increased][decreased] facility-related expenses, primarily related to

$[ ] of [increased][decreased] stock-based compensation expenses, primarily related to

$[ ] of [increased][decreased] other expenses, primarily related to

[ ]; and

$[ ] of [increased][decreased] sublicenses and license fees, primarily related to

[ ].

Read in the reply
In its next report

First report after the company's reply of Jun 23, 2022: 10-Q filed Aug 8, 2022 ↗, against the 10-Q filed May 9, 2022 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2022-07-13

Schedule 14A

2019-04-19 to 2019-04-29 · 2 questions · 2 letters from the SEC, 2 from the company
Review closed 2019-04-29
Proposal 13: Amending and Restating art. 16 of the Articles of Association · Proposal 14: Amending and Restating art. 17 of the Articles of Association, page 64
SEC asked
Please expand your disclosure to briefly state the reasons for and the general effects of the proposed amendments to your Articles of Association. Refer to Item 19 of Schedule 14A. With respect to Proposal 11, please also disclose whether you have any plans, agreements, arrangements or understandings, whether written or oral, relating to the issuance of the additional authorized common shares that will become
Rest of the question

available as a result of the proposed amendment. If none, so state. Refer to Note A to Schedule 14A.

CRSP answered
The Company respectfully advises the Staff that it has revised the disclosure on pages

64, 68, 75, and 76 of the Amended Proxy Statement in response to the Staff’s comment.
Read in the reply
Proposal 13: Amending and Restating art. 16 of the Articles of Association · Proposal 14: Amending and Restating art. 17 of the Articles of Association. , page 64
SEC asked
We note your response to comment 1, which we reissue in part. For each proposal, disclose the rationale for the Board's recommendation and state the effects on your existing shareholders if such amendment is adopted and approved.
Rest of the question

For example, explain the purpose of the increase in authorized share capital that is the subject of Proposal 11, as well as the potential effects that may result, such as dilution, as an illustrative example only. Please explain the rationale for limiting share ownership in the manner described in Proposal 12, and the rationale for limiting shareholder voting rights in the manner described in Proposal 13, and in each case disclose the impact of these proposals. Similarly, we note your disclosure that Proposal 14 is intended to strengthen the power of the Board of Directors. Please expand your disclosure to provide your shareholders with an explanation of the effects of such provision.

CRSP answered
The Company respectfully advises the Staff that it has revised the disclosure on pages 64, 68, 75 and 77 of the Second Amended Proxy Statement in response to the Staff’s comment.
Read in the reply

Also in this review: closing letter, 2019-04-29

Form S-3

2017-11-30 to 2017-12-01 · 1 question · 1 letter from the SEC, 2 from the company
No closing letter
Exhibits
SEC asked
Please file a revised legal opinion that covers the securities that are included in the registration statement.
CRSP answered
The Company respectfully advises the Staff that it has revised Exhibit 5.1 in response to the Staff’s comment.
Read in the reply

Also in this review: company letter, Dec 1, 2017

Form S-1

2016-06-10 to 2016-10-13 · 36 questions · 5 letters from the SEC, 0 from the company
No closing letter
Risk factorsDebtCritical estimatesChina
SEC letter of Jun 10, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Overview, page 1
SEC asked (1)
Please clarify the meaning of any significant scientific or technical terms the first time they are used in order to ensure that lay readers will understand the disclosure. For example, please briefly explain what you mean by “gene editing” at its first use.
CRSP answered

No reply letter found.

Prospectus Summary · Overview, page 1
SEC asked (2)
We note the reference to your “differentiated product development strategy” in the third paragraph. Here or elsewhere, as appropriate, please expand your disclosure to clarify the basis of differentiation. 3
CRSP answered

No reply letter found.

Prospectus Summary · Overview, page 1
SEC asked (3)
We note your statement that the collaboration partners mentioned here will provide over $400 million, inclusive of estimated spending on funded programs. Please revise to clarify the portion of this amount that is subject to certain conditions or milestone events, and the portion that has already been received.
Rest of the question

To the extent you will not receive these funds directly, indicate the entity to which the funds will be paid and your level of ownership in the entity.

CRSP answered

No reply letter found.

Our Strategy, page 1
SEC asked (4)
Please clarify the basis for your statement that you have a “leading position” in the field of gene editing.
CRSP answered

No reply letter found.

Some Of Our In-licensed Patent Applications Are Subject To Priority Disputes …., page 40
SEC asked (5)
Please revise this section or elsewhere in the registration statement, as applicable, to discuss responsibility for costs associated with in-licensed patents, including those related to proceedings before the USPTO or enforcement in courts of applicable jurisdiction.
CRSP answered

No reply letter found.

Market and Industry Data, page 62
SEC asked (6)
Your statement that third party sources do not guaranty the accuracy or completeness of the industry, market and competitive position data may be interpreted as an implied disclaimer. Please revise to clarify that you are liable for this information disclosed in your registration statement.
CRSP answered

No reply letter found.

Critical Accounting Policies and Significant Judgments and Estimates · Determination of Fair Value of Common Shares on Grant Dates, page 84
SEC asked (7)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the IPO and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features.

CRSP answered

No reply letter found.

Our Team, page 89
SEC asked (8)
Please expand your disclosure to explain the role of your six-member scientific advisory board and clarify, here or in the appropriate section of your filing, how members of the board are compensated.
CRSP answered

No reply letter found.

Business · Engineered Cell Therapies..., page 99
SEC asked (9)
Please revise to clarify how the table on page 100 demonstrates the efficiency of CRISPR/Cas9 in multiplexed editing of human primary T-cells. For instance, what does the line above each bar in the table represent? What does the term “allele knock-out” mean and what is its significance to the information provided in the table?
CRSP answered

No reply letter found.

Further Unlocking the Potential of Our CRISPR/Cas9 Platform · Delivery, page 105
SEC asked (10)
We note your statement that you have access to “leading expertise and technology” for lipid nanoparticle based delivery vehicles, or LNPs, through an advisory relationship with Dr. Daniel Anderson at Massachusetts Institute of Technology, and that you are currently testing a variety of LNP technologies for potential use in your therapeutics.
Rest of the question

Please clarify whether these technologies are subject to intellectual property rights and provide risk factor disclosure concerning your use of these technologies, if appropriate.

CRSP answered

No reply letter found.

Intellectual Property, page 106 · In-Licensed Intellectual Property, page 106
SEC asked (11)
We note your statement that “In April 2014, we exclusively licensed certain of Dr. Emmanuelle Charpentier’s rights to a family of patent applications relating to CRISPR/TRACR/Cas9 complexes and their use in targeting or cutting DNA.” Please describe the type of patent protection represented by the application, such as composition of matter, use or process.
Rest of the question

Please provide similar information with respect to the Patent Assignment Agreement noted on page 107.

CRSP answered

No reply letter found.

CRISPR-Owned Intellectual Property, page 106
SEC asked (12)
Please expand your disclosure to clarify the “platform technology” to which the pending patent applications relate, as well as the nature of the protection represented by the application.
CRSP answered

No reply letter found.

Competition, page 112
SEC asked (13)
Please revise your discussion of competitive conditions by describing in greater detail the current landscape for patent protections in your industry. In this regard, we note that across several risk factors on pages 27 to 28 you address specific risks stemming from existing third-party patents and patent applications.
Rest of the question

In your discussion of this landscape, identify specific patents and patent applications, if material, as well as their holders/applicants.

CRSP answered

No reply letter found.

Competition, page 112
SEC asked (14)
Please revise this section to include a discussion of potential competition from CRISPR systems utilizing the Cpf1 protein.
CRSP answered

No reply letter found.

Taxation, page 189
SEC asked (15)
Your disclosure on page 189 concerning the “general” nature of the information inappropriately suggests that you are disclaiming responsibility for the disclosures. Please revise to remove this disclaimer.
CRSP answered

No reply letter found.

Note 4. Variable Interest Entities · TRACR Hematology Limited, page F-18
SEC asked (16)
Please tell us your relationship to Fay Corp. and your accounting treatment within your financial statements including whether or not you consolidate Fay Corp. Reference the authoritative literature on which you relied.
CRSP answered

No reply letter found.

Note 9. Significant Contracts · Collaboration Agreement with Vertex Pharmaceuticals, Incorporated, page F-22
SEC asked (17)
Please refer to the seventh and eighth paragraphs on page F-24. Explain to us why your BESP considers how many options you expect Vertex to exercise. Reference the
CRSP answered

No reply letter found.

Note 9. Significant Contracts · Collaboration Agreement with Vertex Pharmaceuticals, Incorporated, page F-22
SEC asked (18)
Please refer to the last paragraph on page F-24. Provide us an analysis explaining why apparently the options to obtain an exclusive license for up to six Collaboration Targets and a co-exclusive license for hemoglobinopathy or beta-globin targets were not substantive or were priced at a significant and incremental discount in order to justify your accounting for these options as an element of the arrangement for
Rest of the question

which arrangement consideration has been allocated. Reference the authoritative literature on which you relied.

CRSP answered

No reply letter found.

Note 9. Significant Contracts · Collaboration Agreement with Vertex Pharmaceuticals, Incorporated, page F-22
SEC asked (19)
Please refer to the second full paragraph on page F-25. Disclose the amount of the first milestone of the agreement that relates to the exercise of an exclusive option by Vertex to obtain an Exclusive License to commercialize CRISPR/Cas9 technology.
CRSP answered

No reply letter found.

Note 9. Significant Contracts · Collaboration Agreement with Vertex Pharmaceuticals, Incorporated, page F-22
SEC asked (20)
Please refer to the third full paragraph on page F-25. Disclose the amount of the remaining milestones, which you indicate are not substantive, by category (i.e. development, commercialization) and include the number of milestones in each category and the events that trigger payments to you.
Rest of the question

Also reconcile the aggregate of these milestones to the two milestones in the second full paragraph on F-25 and to the $420 million of milestones discussed in the fourth full paragraph on F-23.

CRSP answered

No reply letter found.

General
SEC asked (21)
Please confirm that the images included in your draft registration statement are all of the graphic, visual or photographic information you will be including. If you intend to use any additional images, please provide us proofs of such materials. Please note that we may have comments regarding this material.
CRSP answered

No reply letter found.

General
SEC asked (22)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
CRSP answered

No reply letter found.

SEC letter of Jul 18, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Note 7. Convertible Loans · Conversion of Convertible Loans to Series B Preferred Shares, page F-21
SEC asked (1)
Regarding the conversion of the Bayer convertible loan into Series B Preferred Shares, please provide us an analysis, including specific reference to authoritative literature, supporting your accounting whereby you accounted for the conversion as an accretion and recognized an $8 million charge for interest.
CRSP answered

No reply letter found.

Note 7. Convertible Loans · Conversion of Convertible Loans to Series B Preferred Shares, page F-21
SEC asked (2)
Regarding the conversion of the Vertex convertible loan into Series B Preferred Shares, supporting your accounting as a debt extinguishment and recording an $11.5 million gain.
CRSP answered

No reply letter found.

Note 9. Significant Contracts · Joint Venture with Bayer Healthcare LLC, page F-27
SEC asked (3)
Please provide us an analysis, including specific reference to authoritative literature, supporting the following regarding the Bayer Joint Venture:  For recording your investment in the joint venture upon contributing $.1 million in cash and licensing your proprietary CRISPR/Cas9 gene editing technology and intellectual property for selected disease indications at the fair value of the equity interest in the Joint
Rest of the question

Venture of $36.4 million;  Why it is appropriate to reflect a deferred gain of $63.6 million related to the license before obtaining patent holder consent; and  Why you do not recognize losses of $36.4 million for the three months ended March 31, 2016 for the joint venture considering that your investment is recorded at $36.4 million and therefore has not been reduced to zero.

CRSP answered

No reply letter found.

Exhibit Index
SEC asked (4)
We note you are seeking confidential treatment of portions of certain agreements filed as exhibits. Please note we will provide any comments on your application separately.
CRSP answered

No reply letter found.

SEC letter of Aug 5, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Note 7. Convertible Loans · 2015 Convertible Loan Agreement with Vertex and certain existing shareholders, page F-20
SEC asked (1)
We acknowledge your response to prior comment two. Please provide us a further analysis supporting your conclusion that the conversion feature at the issuance date was not substantive. In this regard, it is not clear from your response why the terms that you address regarding a qualified financing was not considered substantive at the issuance date.
Rest of the question

In addition, please address all conversion terms described herein so as to help us understand why the conversion feature was not considered substantive at the issuance date. Refer to ASC 470-20-40-7 thru 10.

CRSP answered

No reply letter found.

Note 9. Significant Contracts · Joint Venture with Bayer Healthcare LLC, page F-27
SEC asked (2)
We acknowledge your response to prior comment three.  Please tell us how you determined the fair value of the equity interest in the Joint Venture of $36.4 million, which you ascribed as part of the arrangement consideration and why you believe it to be reasonable and complies with ASC 820-10.
Rest of the question

 Please tell us how you determined the $71.4 million fair value of the license and why you believe it to be reasonable and complies with ASC 820-10. Although you disclose that it was determined based on the consideration paid and the fair value of the 50% interest in Casebia, it is unclear to what consideration paid you refer, and how consideration paid and the fair value of your interest in Casebia supports a determination of the fair value of the license.  Tell us why you used fair value rather than selling price in allocating arrangement consideration. Refer to ASC 605-25-30.

CRSP answered

No reply letter found.

SEC letter of Aug 25, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Note 7. Convertible Loans · 2015 Convertible Loan Agreement with Vertex and certain existing shareholders, page F-20
SEC asked (1)
We acknowledge your response to our prior comment one. Regarding your analyses under mandatory conversion in the case of a qualified offering and a conversion into common shares at the price paid by investors in the IPO, tell us:  The authoritative literature supporting your statement that “this feature was not considered a conversion option because the value the holders would receive upon conversion does not vary
Rest of the question

based on the value of the underlying equity at the time of conversion, rather, they would receive a variable number of shares with an aggregate fair value equal to the debt principal outstanding.”  What you mean by your statement “that this feature was ultimately evaluated by the Company as a redemption feature” and the authoritative literature supporting this statement.  The basis for your conclusion that the holders “would receive a variable number of shares with an aggregate fair value equal to the debt principal outstanding” as, based on your disclosure, the holders appeared to receive shares with a fair value less than the debt principal outstanding.  How the Bayer Loan conversion price of $13.43 per share was determined since that is the price used to determine the number of shares into which the Vertex loan is converted.

CRSP answered

No reply letter found.

Note 9. Significant Contracts · Joint Venture with Bayer Healthcare LLC, page F-28
SEC asked (2)
We acknowledge your response to our prior comment two. Please tell us why you chose to value the license based on the total of the fair value of your 50% interest in the joint venture and the $35 million in cash payments from Casebia.
Rest of the question

In this regard, tell us why you went through a process of determining the fair value of Casebia, presumably after completion of its formation and receipt of contributions/commitments by Bayer and you including the license, and why you did not perform a separate valuation of the license. Confirm that the fair value of Casebia for which you based your 50% interest excludes the $35 million in cash payments to be made to you by Casebia. Also, tell us why the total of your 50% interest in the joint venture and the $35 million in cash payments would be representative of fair value of the license considering that they were received as part of a multiple element arrangement.

CRSP answered

No reply letter found.

Note 9. Significant Contracts · Joint Venture with Bayer Healthcare LLC, page F-28
SEC asked (3)
Please provide us an analysis with reference to authoritative literature to support your accounting whereby you intend to recognize the gain on sale of license upon the delivery of the patent holders’ consent.
CRSP answered

No reply letter found.

SEC letter of Oct 13, 2016 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Exhibit 5.1
SEC asked (1)
The opinion that you file must be based on all facts relevant to the issues required to be addressed by Item 601(b)(5), not merely a list of documents that counsel elects to review. Please have counsel revise its opinion accordingly. Please also apply this comment to Exhibit 8.1.
CRSP answered

No reply letter found.

Exhibit 5.1
SEC asked (2)
Regarding the assumptions in paragraphs c) through f) of Part II:  Please explain why assumptions c) and f) are both necessary and appropriate, as they appear to be matters of material fact or law that underlie the ultimate opinion. Tell us whether counsel can rely on certificates of officers or other means rather than include these assumptions, or provide an opinion of counsel that does not include them.
Rest of the question

Regarding assumption f), tell us whether counsel can review public records to determine whether the documents have been amended.  Please explain why assumption d) is necessary and appropriate, given the statement that counsel expresses no opinion as to any auditing matters. Alternatively, please have counsel revise its opinion to remove this assumption.  Assumption e) appears to relate to a readily ascertainable fact. Please have counsel revise its opinion accordingly or tell us why counsel believes why this is not a readily ascertainable fact and why the assumption is necessary. Please also apply this comment to Exhibit 8.1.

CRSP answered

No reply letter found.

Exhibit 5.1
SEC asked (3)
We note the qualification in paragraph a) of Part IV that counsel has “not investigated... any matters of fact.” Please file an opinion based on a review of all legal and factual matters necessary to form the basis of the opinion given. Please also apply this comment to Exhibit 8.1.
CRSP answered

No reply letter found.

Exhibit 5.1
SEC asked (4)
Please tell us why the qualification in paragraph c) of Part IV is necessary and appropriate. Alternatively, file an opinion of counsel that does not contain this assumption.
CRSP answered

No reply letter found.

Exhibit 5.1
SEC asked (5)
Please tell us how the last sentence of the penultimate paragraph is consistent with Section 14 of the Securities Act. Please apply this comment to the similar statements in
CRSP answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 19 letters filed since 2016-06-13. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CRSP/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.